Quantifying ERK-activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling
S. Hamis, Y. Kapelyukh, A. McLaren, C. J. Henderson, C. R. Wolf, M. A. J. Chaplain
This study develops a mathematical model to quantify how dabrafenib and trametinib inhibit ERK-activity in BRAFV600E-mutant melanoma cells and identify mechanisms of drug resistance.
bioRxiv · Apr 20, 2021Cancer Biology